Request Trial
1 February 2013Pharma

Hub and spoke? Life sciences in Northern France

The French biotech and life sciences industry is, if not necessarily booming, more than pulling its weight in a tough economic climate. In the teeth of the worst crisis in living memory, France finds itself playing host to some of Europe’s most innovative companies in the sector, driven by clusters of research and development across the country.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.
Pharma
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
10 November 2026   The pharma giant has filed a trademark and passing off claim in London to try and prevent UK consumers from accessing fake weight-loss drugs and other prescription medicines, after its rival’s success in a similar claim earlier in 2026.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
GSK and Moderna settle cross-border patent dispute over vaccine tech
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
Settled expectations, the six-year rule, and developments in USPTO policy
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
In-house counsel rethink patent filing strategies as costs mount